Fig. 5
Identification of candidate drugs for CRLM patients. (A) Bubble plot of the relationship between approved CRLM drugs and signature genes of MAOS and MAPS. (B) Box plots of the comparison of predicted IC50 of approved CRLM drugs Fluorouracil, Oxaliplatin and Irinotecan between high- and low-MAPS groups. (C) Correlation between the predicted IC50 of candidate drugs (RITA, BAY-87-2243 and lorlatinib) and MAPS scores in CRLM cohort. (D) Correlation between the predicted IC50 of candidate drugs (Obatoclax, BAY-87-2243 and ABT-737) and MAOS scores in CRLM cohort. Lower IC50 values imply greater drug sensitivity. P-values of boxplots and violin plots were obtained from the two-sided Wilcoxon rank-sum test